Better efficacy and lower recurrence rate with guselkumab treatment for generalized pustular psoriasis: A prospective cohort study from China.

Adalimumab Generalized pustular psoriasis Guselkumab Secukinumab Tissue-resident memory T cells

Journal

Clinical immunology (Orlando, Fla.)
ISSN: 1521-7035
Titre abrégé: Clin Immunol
Pays: United States
ID NLM: 100883537

Informations de publication

Date de publication:
05 Jan 2024
Historique:
received: 22 10 2023
revised: 16 12 2023
accepted: 03 01 2024
medline: 8 1 2024
pubmed: 8 1 2024
entrez: 7 1 2024
Statut: aheadofprint

Résumé

Generalized pustular psoriasis (GPP) is a severe and uncommon form of psoriasis, for which treatment options are limited. There is an urgent need to expand the treatment options for GPP. Currently, adalimumab, secukinumab, and guselkumab are considered effective for GPP, but there is a lack of prospective direct comparative studies on their efficacy for GPP. We conducted a prospective, single-center, observational study on 50 GPP patients to compare the efficacy, safety, and recurrence rates of these three biologics. Adalimumab, secukinumab, and guselkumab resulted in varying degrees of improvement in patients with GPP, but guselkumab exhibited superior efficacy and a lower recurrence rate than the other two drugs. This enhanced response may be attributed to the significant reduction in CD8+ tissue-resident memory T cells within GPP lesions caused by guselkumab.

Identifiants

DOI: 10.1016/j.clim.2024.109899 PMID: 38185271
pubmed: 38185271
pii: S1521-6616(24)00010-X
doi: 10.1016/j.clim.2024.109899
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

109899

Informations de copyright

Copyright © 2024. Published by Elsevier Inc.

Déclaration de conflit d'intérêts

Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Auteurs

Jiajing Lu (J)

Department of Dermatology, Shanghai Skin Disease Hospital, Tongji University, Shanghai 200443, China; Institute of Psoriasis, Tongji University School of Medicine, Shanghai 200443, China.

Dawei Huang (D)

Department of Dermatology, Shanghai Skin Disease Hospital, Tongji University, Shanghai 200443, China; Institute of Psoriasis, Tongji University School of Medicine, Shanghai 200443, China; Department of Dermatology, Shanghai Skin Disease Hospital, Tongji University, Shanghai 200443, China.

Nan Yang (N)

Department of Dermatology, Shanghai Skin Disease Hospital, Tongji University, Shanghai 200443, China; Institute of Psoriasis, Tongji University School of Medicine, Shanghai 200443, China; Department of Dermatology, Shanghai Skin Disease Hospital, Tongji University, Shanghai 200443, China.

Hui Qin (H)

Department of Dermatology, Shanghai Skin Disease Hospital, Tongji University, Shanghai 200443, China; Institute of Psoriasis, Tongji University School of Medicine, Shanghai 200443, China; Department of Dermatology, Shanghai Skin Disease Hospital, Tongji University, Shanghai 200443, China.

Yingyuan Yu (Y)

Department of Dermatology, Shanghai Skin Disease Hospital, Tongji University, Shanghai 200443, China; Institute of Psoriasis, Tongji University School of Medicine, Shanghai 200443, China.

Xiaoyuan Zhong (X)

Department of Dermatology, Shanghai Skin Disease Hospital, Tongji University, Shanghai 200443, China; Institute of Psoriasis, Tongji University School of Medicine, Shanghai 200443, China.

Luyang Kong (L)

Department of Dermatology, Shanghai Skin Disease Hospital, Tongji University, Shanghai 200443, China; Institute of Psoriasis, Tongji University School of Medicine, Shanghai 200443, China.

Yuxiong Jiang (Y)

Department of Dermatology, Shanghai Skin Disease Hospital, Tongji University, Shanghai 200443, China; Institute of Psoriasis, Tongji University School of Medicine, Shanghai 200443, China.

Jing Zhou (J)

Department of Dermatology, Shanghai Skin Disease Hospital, Tongji University, Shanghai 200443, China; Institute of Psoriasis, Tongji University School of Medicine, Shanghai 200443, China. Electronic address: vine_vs_vine@126.com.

Yuling Shi (Y)

Department of Dermatology, Shanghai Skin Disease Hospital, Tongji University, Shanghai 200443, China; Institute of Psoriasis, Tongji University School of Medicine, Shanghai 200443, China. Electronic address: shiyuling1973@tongji.edu.cn.

Classifications MeSH